Results 81 to 90 of about 328,188 (291)
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Background Most clinical trials with time-to-event primary outcomes are designed assuming constant event rates and proportional hazards over time. Non-constant event rates and non-proportional hazards are seen increasingly frequently in trials.
Kim Jachno +2 more
doaj +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Out of order: specification check sequencing in Cox models
The Cox duration model serves as the basis for more complex duration models like competing risks, repeated events, and multistate models. These models make a number of assumptions, many of which can be assessed empirically, sometimes for substantive ends.
Benjamin T. Jones, Shawna K. Metzger
doaj +1 more source
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
A transformer model for cause-specific hazard prediction
Backgroud Modelling discrete-time cause-specific hazards in the presence of competing events and non-proportional hazards is a challenging task in many domains.
Matthieu Oliver +4 more
doaj +1 more source
Cox Regression in Survival Analysis: Practical Insights for Clinicians
Survival analysis is a fundamental tool in clinical research for evaluating time-to-event outcomes. While the Kaplan-Meier method remains a widely used univariable approach for estimating survival probabilities and comparing groups, it does not account ...
António Gomes +3 more
doaj +1 more source
Analysing wage differences between the USA and Germany using proportional hazards models [PDF]
We analyse differences between the wage distributions in the USA and Germany in 2001 both for women and men. The empirical analysis is based on the decomposition of differences using Cox's marginal (partial) likelihood.
Behr, Andreas, Pötter, Ulrich
core

